Pipeline
Pipeline
Tenvie is advancing its wholly owned portfolio of small molecule programs to address neurological, inflammatory, cardiometabolic, and ophthalmologic diseases. We deliver substantial program optionality across biological mechanisms with pipeline-in-a-product opportunities. We maximize potential patient impact by developing peripherally restricted small molecules derived from our CNS-penetrant chemotypes.